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Certain thalassemic human 0-globin pre-mRNAs carry mutations that generate aberrant splice sites and/or
activate cryptic splice sites, providing a convenient and clinically relevant system to study splice site selection.
Antisense 2'-O-methyl oligoribonucleotides were used to block a number of sequences in these pre-mRNAs and
were tested for their ability to inhibit splicing in vitro or to affect the ratio between aberrantly and correctly
spliced products. By this approach, it was found that (i) up to 19 nucleotides upstream from the branch point
adenosine are involved in proper recognition and functioning of the branch point sequence; (ii) whereas at least
25 nucleotides of exon sequences at both 3' and 5' ends are required for splicing, this requirement does not
extend past the 5' splice site sequence of the intron; and (iii) improving the 5' splice site of the internal exon
to match the consensus sequence strongly decreases the accessibility of the upstream 3' splice site to antisense
2'-O-methyl oligoribonucleotides. This result most likely reflects changes in the strength of interactions near
the 3' splice site in response to improvement of the 5' splice site and further supports the existence of
communication between these sites across the exon.
Pre-mRNA splicing takes place within a large ribonucleo-
protein complex termed the spliceosome. The specificity and
accuracy of splicing are determined by the interactions of small
nuclear ribonucleoprotein particles and protein components of
the spliceosome with a number of pre-mRNA sequence ele-
ments in pre-mRNA, such as the branch point sequence, the
polypyrimidine tract, and the 3' and 5' splice sites (reviewed in
references 15, 21, and 29). In addition, exon sequences seem to
contribute to the specificity of splicing (references 35, 41, and
49 and references therein). However, besides identification of
a regulatory element in the female-specific exon of the dou-
blesex pre-mRNA (17, 19, 30) and characterization of purine-
rich motifs in exons from some other spliced transcripts (7, 12,
27, 45, 47, 49, 51), the involvement of exon sequences in
splicing remains unclear.
In this work, we have used antisense 2'-O-methyl oligoribo-
nucleotides (see reference 43 for a review) to study the
function of several intron and exon sequences in pre-mRNA
splicing. This approach stems from our recent report which
showed that the binding of 2'-O-methyl oligoribonucleotides to
the branch point or aberrant splice sites leads to the restora-
tion of correct in vitro splicing of mutated P-globin pre-
mRNAs identified in individuals with various forms of
3-thalassemia (11). These oligonucleotides form strong du-
plexes with RNA which are resistant to RNase H and RNA
unwinding activities. In consequence, they remain stably asso-
ciated with the complementary regions in RNA, efficiently
inhibiting the function of the targeted sequences. Antisense
2'-O-methyl oligoribonucleotides were originally used as se-
quence-specific probes to study the structure of small nuclear
ribonucleoproteins and their interactions with the pre-mRNA
substrate (43). They were also used to search for novel
cis-acting sequence elements and possible scanning mecha-
nisms during the splicing reaction (28).
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We have targeted these oligonucleotides against human
13-globin pre-mRNAs carrying mutations responsible for a
number of 1-globin thalassemia variants. The mutations gen-
erate new splice sites and/or activate cryptic ones, leading to
aberrant splicing pathways (reviewed in reference 40). In the
experiments described below, we took advantage of the fact
that changes in the accumulation of the correctly spliced
products relative to that of the aberrant ones provide a
sensitive and internally controlled assay for monitoring inter-
ference with the activity of the sequence targeted by the
antisense oligonucleotide. Using this approach, we have found
that sequences upstream from the conserved branch point
sequence as well as those within the exons are required for
splicing and play a role in splice site selection. The experiments
also showed that improving the 5' splice site of the internal
exon affects interactions at the upstream 3' splice site.
MATERIALS AND METHODS
Plasmid construction. Previously described pSP64HPA6
(22) and its thalassemic derivatives cloned in the pSP64 vector
were used in all studies. The pIVS1-P110 clone, carrying an
A-to-G mutation in position 110 of the first intron, was
constructed by subcloning an appropriate fragment from the
original thalassemic clone (14a). The pIVS2-13705 clone was
obtained by introducing a T-to-G mutation at position 705 of
the large ,B-globin intron in the pIVS2 clone, as previously
described (11, 25). A C-to-T mutation at position 654 and a
TA-to-GT mutation at positions 657 and 658 of the large
13-globin intron in the pIVS2 clone were introduced to create
pIVS2-f3654 and pIVS2-p654,°n clones, respectively. The struc-
tures of all mutated constructs were confirmed by sequencing.
In vitro transcription and splicing. 32P-labeled transcripts
were synthesized as previously described (20) with SP6 RNA
polymerase (Promega) and DNA templates cleaved within the
second exon at either the BamHI site (clones HPA6 and ,llO),
the PvuII site (clone 3705), or the AseI site (clones pIVS2, 13654,
and 13651,on). The preparation of nuclear extract from HeLa
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TABLE 1. Oligonucleotides used in this study












3'ss 579/14 UAUUGCCCUGAAAG 43








5'ss 705 CCUCUUACCUCAGUUAC 47
Intl UAUUAGCAAUAUGA 21
Int2 UUGUAGCUGCUAUU 36
5'ss 652/18 GCUAUUACCUUAACCCAG 44
5'ss 652con/18 GCACUUACCUUAACCCAG 50
5'ss 652con/14 CACUUACCUUAACC 43
cells and in vitro splicing were performed as previously de-
scribed (11, 22).
Synthesis and purification of oligonucleotides. 2'-O-methyl-
ribonucleoside phosphoramidates (Glen Research, Sterling,
Va.) were used for oligonucleotide synthesis in an Applied
Biosystems synthesizer at the Lineberger Comprehensive Can-
cer Center. Oligonucleotides were purified by thin-layer chro-
matography (SurePure kit; U.S. Biochemicals), and their con-
centrations were determined spectrophotometrically at 260
nm. To ascertain the quality of oligonucleotides, the 5'_32p_
labeled compounds were analyzed by polyacrylamide gel elec-
trophoresis.
Oligonucleotide treatment. In all experiments, 2'-O-methyl
oligoribonucleotides were added to the reaction mixture to-
gether with the other components of the splicing reaction. The
preannealing of oligonucleotides with transcript in the absence
of nuclear extract has been shown not to increase their overall
effect on splicing (11, 28). The extent of unspecific effects for
each experiment was controlled by using oligonucleotides with
no complementarity to the RNA substrate. Oligonucleotide
3'ss 579/14 was used to control unspecific effects during the
splicing of pre-mRNAs containing the first 1-globin intron,
whereas oligonucleotide BPa was used during the splicing of
pre-mRNAs containing the second intron. In some experi-
ments, a mixture of randomly synthesized oligonucleotides was
also used.
Sequences of oligonucleotides. The oligonucleotides used in
this study are listed in 5'-to-3' orientation in Table 1.
Data processing and analysis. All autoradiograms were
captured by a DAGE MTI CCD72 video camera (DAGE,
Michigan City, Ind.), and images were processed with NIH
Image 1.47 and MacDraw Pro 1.0 software. The final figures
were printed out on a Sony dye sublimation printer. Results
were quantitated with NIH Image 1.47 software and expressed
as percentages of correct product relative to the sums of
correct and aberrant products. Values were adjusted to ac-
count for the higher number of 32P-labeled C nucleotides in
the longer, aberrantly spliced product. Averages obtained from
several independent experiments and multiple exposures are
presented.
RESULTS
Mapping the upstream boundary of the functional domain
near the branch point sequence with 3110 pre-mRNA sub-
strate. A G-to-A point mutation at position 110 of the first
intron in the 1-globin gene (IVS1-P13-; Fig. 1B) creates a new
3' splice site at position 109 in addition to the one located
at position 130 of this intron. This mutation is responsible for
a significant number of 1-thalassemia cases in southeastern
Europe, Cyprus, and Lebanon (40). The splicing of IVS1-P'10
mutant pre-mRNA leads to predominant (approximately 90%)
accumulation of a spliced product containing an additional
19 nucleotides of the intron sequence (Fig. 2A, lane 1).
Remarkably, aberrant splicing of 13flO pre-mRNA occurs via
selection of the regular branch point at position 94 of the
intron, whereas correct splicing (approximately 10% of the
resultant mRNA) occurs via selection of the cryptic branch
point at position 107 (54). As a result, mutations inactivating
the regular branch point (38) or antisense oligonucleotides
blocking it (11) stimulate the cryptic branch point and restore
correct splicing in the ,131o background.
In these studies, we used 2'-O-methyl oligoribonucleotides
to determine the importance of sequences located upstream
from the branch point region in the function of this splicing
element. We have designed a series of 14-mers complementary
to the region extending up to 32 nucleotides upstream from the
branch point sequence (Fig. 1B). The ability of oligonucleo-
tides to inhibit splicing at the aberrant 3' splice site and at the
same time to promote splicing at the correct 3' splice site was
taken as the measure of the function of the upstream se-
quences during the splicing of 1P"o pre-mRNA (11). Note that
a concomitant switch in selection between the regular and
cryptic branch points can be directly determined on autoradio-
grams because of the variable mobility of the corresponding
lariats (54).
The results of in vitro splicing of 110 pre-mRNA carried
out in the presence of 0.5, 2.0, and 10.0 ,uM oligonucleo-
tide BPa, blocking all seven nucleotides of the branch point
sequence, are shown in Fig. 2A. Consistent with the results of
a previous report (11), the antisense 2'-O-methyl oligoribo-
nucleotide targeted to this site leads to a change in the ratio
between correct and aberrant products. A splicing reaction
carried out at a 2 ,uM concentration of this oligonucleotide
results in the accumulation of approximately 55% of the
correct product (Fig. 2A, lane 3; see Fig. 2C for quantitation).
Although 10 ,uM oligonucleotide BPa results in a marked
decrease of the overall efficiency of the splicing reaction, it
does not significantly modify the ratio between correct and
aberrant products achieved at a 2 ,uM concentration (Fig. 2A,
lane 4).
Figure 2B demonstrates the results of an in vitro splicing
reaction of 110 pre-mRNA carried out in the presence of a 2
jLM concentration of oligonucleotides directed upstream from
the branch point adenosine. Similar to BPa, oligonucleotides
BPb, -c, and -d restore correct splicing to 50 to 65% (Fig. 2B,
lanes 2 to 4, respectively, and C). Note that oligonucleotides
BPc and BPd hybridize immediately outside the conserved
branch point sequence and four nucleotides upstream from
this element, respectively. While oligonucleotide BPe, hybrid-
ized 13 nucleotides upstream from the branch point adenosine,
still has some effect on the splicing pathway, oligonucleotide
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FIG. 1. (A) Structure of human 3-globin pre-mRNA (not drawn to scale) containing the first intron (the line) and two flanking exons (boxes).
The positions of the regular (BP) and cryptic (bp) branch point adenosines, 3l1o mutation, and the 3' splice site (3'ss) are shown. The regions of
pre-mRNA used as targets for 2'-O-methyl oligoribonucleotides are indicated by double-headed arrows. Exon 1 contains 154 nucleotides, and exon
2 contains 210 nucleotides. The exact sequence positions of oligonucleotides BPa to BPf (B) and Exa to Exd (C) are shown. The regular and cryptic
branch point sequences (shaded boxes) and the aberrant (131 0) and correct 3' splice sites are indicated.
BPf, targeted 5 nucleotides further upstream, seems to be
ineffective. Consistently, oligonucleotide BPf, in contrast to the
other probes tested, does not stimulate the formation of the
lariat intermediate at the branch point adenosine at position
107, as indicated by the lack of a band migrating to the top of
the gel (Fig. 2B, lane 6).
The involvement of exon sequences in the splicing of PV"0
pre-mRNA. To survey other regions of 3-globin pre-mRNA for
the existence of functional domains involved in splicing, we
designed 14-mers complementary to the correct junction be-
tween the first intron and the second exon (oligonucleotide
Exa) or to sequences extending downstream into the second
exon (oligonucleotides Exb to -d) (Fig. 1C). For H13A6 pre-
mRNA, oligonucleotide Exa partially overlaps with the intron
sequence; in the case of 131lo substrate, the same oligonucleo-
tide has its target entirely within the aberrantly spliced second
exon. Although the upstream end of the duplex formed
between this oligonucleotide and its target in the p"O tran-
script is separated from the predominantly used aberrant 3'
splice site by 14 nucleotides, Exa oligonucleotide at a 2 ,uM
concentration fully blocks splicing (Fig. 3, lane 3). This is in
agreement with the observation that mutations disrupting the
AG dinucleotide of the normal 3' splice site inhibit the use of
the aberrant splice site in 110 pre-mRNA (23, 54). An
inhibitory effect on splicing is also observed in the presence of
oligonucleotides Exb and Exc, which hybridize further down-
stream into the second exon, and, albeit to a lesser extent, in
the presence of the most distal oligonucleotide, Exd, which
hybridizes 44 nucleotides downstream from the 110 3' splice
site (Fig. 3, lanes 4 to 6). The control noncomplementary
oligonucleotide does not significantly affect the efficiency of the
splicing reaction (Fig. 3, lane 7). A pattern of inhibition similar
to that described above was obtained when each of the
oligonucleotides Exa, -b, -c and -d was added to the splicing
reaction with normal ,B-globin pre-mRNA (data not shown).
The involvement of exon sequences in the splicing of the
p705-globin pre-mRNA. The results of Zhuang and Weiner
(54) suggested that the splicing of 110 pre-mRNA may
represent
a special case in which the AG dinucleotide located inside
the exon is required for splicing at the upstream 3' splice site.
To confirm that exon involvement in splicing is not limited
to only one type of substrate, we analyzed the effects of a
series of antisense oligonucleotides (Fig. 4B and C) on the
splicing of thalassemic 1705 pre-mRNA. A T-to-G mutation
at position 705 of the large ,B-globin intron creates an addi-
tional 5' splice site and activates a cryptic 3' splice site at
position 579 of this intron (8). The incorrect splicing path-
way resulting from the utilization of both splice sites leads to
the incorporation of nucleotides 580 to 705 of the intron into
the spliced product and the accumulation of significant
amounts of the 577-nucleotide aberrant RNA in addition to
the correct product (Fig. 4A). Changes in the ratio between
correct and aberrant products provide a sensitive method for
measuring the sequence-specific effects of the oligonucleotides
used.
Figure 5A shows the complete pattern of in vitro splicing of
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FIG. 2. (A) Change in the ratio between correct and aberrant products during the splicing of 110 pre-mRNA in the presence of oligonucleotide
BPa, targeted to the branch point sequence. The concentration of oligonucleotide is shown at the top of each lane. The control splicing pattern
for 3110 pre-mRNA is shown in lane 1. Bands at the top of the autoradiogram correspond to the lariat-exon 2 intermediate, formed at the cryptic
branch point at nucleotide 107 (upper) and at the regular adenosine at nucleotide 94 (lower). The 249-nucleotide RNA product visible in lanes
3 and 4 is generated by endogenous 3'-to-5' exonuclease (3' Exo) blocked at the site of duplex formation (reference 11 and unpublished data).
The structures of splicing products and intermediates are shown on the right, and their sizes (in nucleotides) are on the left. An asterisk denotes
the unusual mobility of the corresponding lariat-containing RNA species. The same designations are used in subsequent figures. (B) Effects of
oligonucleotides BPb to BPf, targeted upstream from the branch point adenosine, on the splicing of 1311o pre-mRNA. (C) Quantitative analysis of
the reactions carried out in the presence of 2 ,uM oligonucleotides. Data were calculated as the percentages of the correct product in overall
splicing (see Materials and Methods).
of correct to aberrant products is approximately 1:1 (Fig. 5B,
lane 1). Aberrant splicing is almost completely suppressed
in the presence of 2 ,uM 14-mer oligonucleotides targeted
either to the 3' splice site (oligonucleotide 3'ss 579; Fig. 5B,
lane 2) or to the exon sequence immediately downstream
from this site (oligonucleotide ExUl; Fig. SB, lane 3). Oligo-
nucleotides targeted to exon sequences between nucleo-
tides 7 and 20 (ExU2), 16 and 30 (ExU3), and 27 and 40
(ExU4) also block aberrant splicing, although not as efficient-
ly as the first two probes mentioned immediately above (Fig.
5B, lanes 4 to 6, respectively). The most distant probe (oligo-
nucleotide ExU5), complementary to nucleotides 37 to S0 of
the exon, has only a limited effect on the aberrant splicing
pathway of 3705 pre-mRNA and delimits the downstream
boundary of the exon region that plays a role in splicing (Fig.
5B, lane 7).
The involvement of exon sequences in splice site selection
was further confirmed by using oligonucleotides ExD1 and
ExD2, which hybridize to a region near the downstream end of
the exon and lead to virtually full inhibition of the aberrant
splicing pathway (Fig. SC, lanes 2 and 3). As expected (11), a
strong inhibitory effect is also mediated by oligonucleotide 5'ss
705, targeted to the exon-intron junction (Fig. SC, lane 4).
Interestingly, oligonucleotides Intl and Int2, targeted to re-
gions located entirely within the intron and almost immediately
downstream from the 5' splice site, have little, if any, effect on
aberrant splicing (Fig. 5C, lanes S and 6).
Testing the accessibility of 3' and 5' splice sites to 2'-O-
methyl oligonucleotides in I654 and 1654con pre-mRNAs. It has
been shown for a variety of pre-mRNA substrates that muta-
tions within the 5' splice site of an internal exon affect the
splicing of the upstream intron (1, 10, 26, 31, 46). This effect
suggests the existence of a certain type of communication
between splice sites across the exon and argues in favor of the
exon definition model (36). In order to determine whether an
improvement of the 5' splice site to the consensus sequence
increases interactions near the upstream 3' splice site flanking
the internal exon, we tested the accessibility of these sites to
antisense oligonucleotides in 13654-globin pre-mRNA and its
modified version, 13654con. 1654 represents another thalassemic
mutation which occurs in the human 1-globin gene and results
in the generation of aberrantly spliced product, containing part
of the second intron (5). The C-to-T mutation at nucleotide
654 of the intron creates a new 5' splice site at position 652
(AG/GUAAUA), activates a cryptic 3' splice at position 579,
and results in the generation of a 73-nucleotide aberrant exon
(Fig. 6). We improved the aberrant 5' splice site at position 652
by two point mutations, including a highly conserved G at
position +5, thereby creating the consensus element AG/
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FIG. 3. Inhibition of splicing by oligonucleotides targeted to aber-
rant exon 2. The splicing of 110-globin pre-mRNA in the presence of
2,uM oligonucleotides Exa to Exd is shown in lanes 3 to 6, respectively.
The splicing reactions of H13A6 and f3110 pre-mRNAs with no oligo-
nucleotides are shown in lanes 1 and 2, respectively. Lane 7, the
splicing of 311 pre-mRNA in the presence of noncomplementary
oligonucleotide (control) (see Materials and Methods).
changes increase the base pairing of the 5' splice site to the 5'
end of Ul small nuclear RNA and result in more efficient
selection of this site (32, 52, 53). The full splicing patterns for
both the original (,13654) and improved (135Ofn) pre-mRNAs
are shown in Fig. 7 (lanes 2 and 3, respectively). In addition,
the pattern for wild-type pre-mRNA, containing no mutation
in the intron, is presented in lane 1 of Fig. 7. As expected,
creation of the perfect 5' splice site at position 652 leads to
complete inclusion of the aberrant exon.
Consistent with the results of a previous report (11), 18-mer
oligonucleotides targeted to either 3' or 5' splice sites in 13654
pre-mRNA inhibit the aberrant splicing pathway with similar
efficiency. At 0.25 ,uM concentrations, both oligonucleotides
lead to a substantial reduction in the amount of the aberrant
product (Fig. 8A, lanes 2 and 5); at 0.75 ,uM concentrations,
they lead to full restoration of the correct pathway (Fig. 8A,
lanes 3 and 6). On the basis of these results, we conclude that
in p654 pre-mRNA, 3' and 5' splice sites are equally accessible
to antisense oligonucleotides. The results of a similar analysis
with 13651on pre-mRNA are markedly different. An 18-mer
targeted to the 5' splice site restores correct splicing with an
efficiency not drastically different from that in the splicing of
p654 pre-mRNA (Fig. 8B, lane 5), in spite of the fact that a
strong consensus 5' splice site leads to exclusively aberrant
splicing of p654,on pre-mRNA (Fig. 8B, lane 1). In contrast, an
18-mer targeted to the 3' cryptic splice site that at 0.25 ,uM
efficiently restored correct splicing of p654 pre-mRNA is
inactive at this concentration when targeted to the same site in
13654con pre-mRNA (Fig. 8B, lane 2). Some effect becomes
detectable at 0.75,uM (Fig. 8B, lane 3), and only at 2.5,uM is
correct splicing fully restored (Fig. 8B, lane 4). These results
demonstrate that the 3' splice site in P"65"'on pre-mRNA is a
much more resistant target for 2'-O-methyl oligoribonucleo-
tides than the engineered consensus 5' splice site.
The difference in relative accessibility between aberrant 3'
and 5' splice sites in 13654con pre-mRNA is even more apparent
when they are targeted with 14-mers. The oligonucleotide
targeted to the 3' splice site in p165on is totally ineffective even
at a 2.5,uM concentration, whereas the one targeted to the 5'
splice site restores 30% of correct splicing at a 0.25 ,uM
concentration and 70% at a 2.5,uM concentration (Fig. 9A,
lanes 4 and 5, respectively). The inactivity of the 14-mer
targeted to the 3' splice site does not result from any reason
other than the low accessibility of the target site in 13654con
pre-mRNA (for example, the formation of the secondary
structure), since the same preparation of this oligonucleo-
tide at a 0.25 ,uM concentration leads to 70% of the cor-
rect product (Fig. 9B, lane 2) and at a 2.5,uM concentration
leads to virtually full inhibition of the aberrant splicing path-
way of 3654 pre-mRNA (Fig. 9B, lane 3). The control oligonu-
cleotide tested with both pre-mRNAs at a 2.5,uM concentra-
tion does not affect the splicing reaction (Fig. 8B, lane 8, and
9B, lane 4).
DISCUSSION
To determine the upstream boundary of the functional
domain near the branch point sequence, we used several
antisense 2'-O-methyl oligoribonucleotides complementary to
targets upstream from the regular branch point in p"1' pre-
mRNA. The results show that no more than 19 nucleotides
upstream from the branch point adenosine are involved in the
proper recognition and functioning of this splicing element.
Previously reported data revealed several possible boundaries
for the branch point domain, varying in length from 5 to 39
nucleotides upstream from the branch adenosine (3, 37). Since
those results were based on RNase A and RNase Ti protection
assays, the heterogeneity in the size of the protected region
could result from either overdigestion or underdigestion by
enzymes (37). Furthermore, since 2'-O-methyl oligoribonucle-
otides remain stably associated with target RNA and prevent
interactions with splicing factors throughout the entire course
of the splicing reaction, they offer an experimental approach
different from that of the nuclease protection assay (3, 4, 24,
37) or oligonucleotide-mediated cleavage of RNA by RNase H
(37, 39). The last two methods detect only those interactions
between RNA and splicing factors that exist at the time of
nuclease treatment.
Oligonucleotides BPa and BPb are targeted to the regular
branch point and at the same time to 12 and 16 nucleotides
upstream from the cryptic branch point sequence, respectively.
The binding of these oligonucleotides to pre-mRNA also
seems to affect the function of this branch point and leads to
the activation of yet another branch point (most likely the
adenosine at position 115), as indicated by the generation of an
additional slowly migrating intermediate at the top of the gel
(Fig. 2A, lane 3, and B, lane 2). More distant oligonucleotide
probes (BPc to Bpe), effective in blocking the regular branch
point, have their targets beyond the cryptic branch point
domain and do not affect its function. This observation addi-
tionally supports the postulated extent of interactions up-
stream from the branch point sequence. The mapping of
interactions from the downstream side of the branch point
sequence by using the same approach was not possible, pre-
sumably because of the proximity of the polypyrimidine tract
VOL. 14, 1994
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FIG. 4. (A) Structure of 1705 pre-mRNA. This RNA contains the 126-nucleotide aberrant exon created by a mutation at position 705 of the
850-nucleotide ,-globin intron 2. The position of the p654 mutation (see also Fig. 6) is indicated above the aberrant exon. The correct exon 1
contains 222 nucleotides; exon 2 contains 229 nucleotides. Aberrant introns 1 and 2 contain 579 and 145 nucleotides, respectively. The regions of
pre-mRNA used as targets for 2'-O-methyl oligoribonucleotides are indicated by double-headed arrows. (B and C) These oligoribonucleotides are
shown in more detail as bars below the intron sequence. The 5' splice site at position 705 is indicated by the shaded box.
and the cryptic branch point. Targeting oligonucleotides to this
region inhibited both splicing pathways simultaneously (refer-
ence 11 and data not shown).
Although it has been known that both the sequences (6, 12,
14, 35, 41, 49, 51) and the lengths (2, 9, 13, 14, 34, 44, 48, 51)
of exons are important determinants in the mechanism of
splice site selection, the details of their involvement are not
well understood. We have presented here a method for
probing exon sequences with 2'-O-methyl oligoribonucleotides
in search of the signals required for splice site selection. The
existence of one such signal, the AG dinucleotide of the
correct 3' splice site originally identified by genetic analysis of
the 3110 mutant (23, 54), was confirmed here by masking it with
the antisense oligonucleotide Exa. Interestingly, nonconserved
regions of the exon located further downstream, beyond the
AG dinucleotide, also seem to play an important role in
splicing. This is demonstrated by the inhibitory effects of
oligonucleotides Exb and -c. The effect of oligonucleotide Exd,
which hybridized to nucleotides 26 to 40 of the exon, was not
as pronounced, suggesting that the boundary of exon se-
quences important for splicing lies within this region. This may
explain why in another study (28) an oligonucleotide that was
two nucleotides shorter and targeted to the same region failed
to show any inhibitory effect.
Although splicing inhibition was reproducibly observed in
several independent experiments, the possibility that the de-
creased efficiency of splicing in the presence of oligonucleo-
tides Exa, -b, -c, and -d was in fact caused by their unspecific
effects or resulted from normal variabilities between splicing
reactions could not be ruled out. An internally controlled
system was provided by p705 pre-mRNA. Oligonucleotides
ExUl to -4 targeted to the aberrant exon in this substrate,
resulted in predominant accumulation of the correct product
instead of an overall inhibition of splicing, confirming the
specificity of the observed effect. Since oligonucleotide ExU5
was not able to switch splicing pathways, we conclude that the
essential region of the aberrant exon is limited to 27 to 36
nucleotides downstream from the 3' splice site (upstream
limits for ExU4 and ExU5 targets, respectively), i.e., similar
to the analogous region in H1A6 pre-mRNA. The region
essential for splicing upstream from the 5' splice site does
not appear to be shorter than 20 nucleotides and could
be as extensive as the one at the other end of the exon. In
contrast, the upstream region of the intron required for
splicing is limited almost exclusively to the aberrant 5' splice
site. Although the target for oligonucleotide Intl is separated
from the 3' flanking nucleotide of this splice site by only
four nucleotides, the oligonucleotide did not promote correct
splicing. This result argues against the possibility that the
binding of 2'-O-methyl oligoribonucleotides to RNA gene-
rates long-range changes in the required structure of the
substrate pre-mRNA and prevents the association of splic-
ing factors at locations distant from the site of duplex forma-
tion. Such a remote effect would significantly decrease the











SPLICING DOMAINS IN PRE-mRNA 7451
A R
2pM 2pM
1079t[* C;< o) " = : =< zJ S CM @ ECD E
-m 0cto
a5a-i coet 41- f _i coec
c x x 0
......... aM
Q'- M berrant 'aberrant










1 2 3 4 5 6 7
LANE NUMBER
FIG. 5. (A) Complete pattern of products and intermediates generated during in vitro splicing of 1705 pre-mRNA. The reaction proceeds by
two pathways, leading to the accumulation of correctly and aberrantly spliced products. Large lariat structures at the top of the gel comigrate at
the concentration of acrylamide used in this experiment (8%). The structures and sizes of all RNA species were determined previously (11) and
are shown on the right and the left of the autoradiogram, respectively. Aberrant 3' and 5' splice sites are represented by short vertical lines in the
intron. The same designations are used in subsequent figures. (B) Change in the ratio between correct and aberrant products by oligonucleotides
3'ss 579 and ExUl to ExU5. The splicing reaction of p, 05 pre-mRNA was carried out in the presence of 2 ,uM oligonucleotides targeted to the
aberrant 3' splice site (oligonucleotide 3'ss 579 [lane 2]) and to upstream sequences of the aberrant exon (oligonucleotides ExUl to ExU5 [lanes
3 to 7, respectively]). Lane 1, control splicing with no oligonucleotide. For simplicity, only the part of the autoradiogram which contains spliced
products is shown here and in panel C. Quantitation of the results is shown below the autoradiogram. (C) Effects of oligonucleotides targeted to
sequences near the aberrant 5' splice site. The splicing of 13705 pre-mRNA was carried out in the presence of oligonucleotides targeted to the
downstream part of the aberrant exon (oligonucleotides ExD1 and ExD2 [lanes 2 and 3]), the 5' splice site at position 705 (oligonucleotide 5'ss
705 [lane 4]), and adjacent intron sequences (oligonucleotides Intl and Int2 [lanes 5 and 6]). Lane 7, splicing with noncomplementary
oligonucleotide.
timating the actual boundaries of the domains involved in
splicing.
Several lines of evidence show that the lack of effect for
certain oligonucleotides is not due to their inherent inability to
hybridize to the target sequence. A sequence comparison of
the oligonucleotides tested in this work suggests that their
a
(572) UCUUUCAGIGGCAAUAAUGAUACAAUGUAUCAUGCCUCUUUGCACCAUUC (620)
I - --- t-nernr
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(621) UAAAGAAUAACAGUGAUAAUUUCUGGGUUA GCAAUAUUUC (668)
l er
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FIG. 6. Sequence of the 73-nucleotide aberrant exon in 13654 pre-
mRNA. The cryptic 3' splice site at position 579 and the 5' splice site
(shaded box) created by the mutation at position 654 of 1-globin intron
2 are indicated. The two-nucleotide mutation resulting in the genera-
tion of the consensus 5' splice site p651,n is shown above the shaded
box. The positions of 14- and 18-mer 2'-O-methyl oligoribonucleotides
targeted to both splice sites are indicated below the sequence.
different compositions and hence potential variations in the
strength of binding to target sequences did not contribute
significantly to their differences in the ability to affect splicing.
For example, oligonucleotides Intl and Int2, with 21 and 36%
GC content, respectively, are ineffective, although they are
expected to anneal to complementary sequences on RNA with
higher affinity than the effective oligonucleotides ExD1 (14%
GC) and ExD2 (21% GC). Oligonucleotides BPb and BPf,
with an identical GC content (48%), exert drastically different
effects, consistent with their respective distances from the
branch point sequence. Furthermore, one oligonucleotide (3'ss
579/14) affects splicing when targeted to the 3' cryptic splice
site sequence in p654 pre-mRNA but does not affect splicing if
targeted to the same sequence in p654con pre-mRNA. Finally,
direct evidence is provided by the fact that oligonucleotides
BPf and BPc, with very different effects on splicing, served
equally efficiently as primers in a primer extension experiment
(data not shown).
The results presented in this work demonstrate that approx-
imately 50 to 55 nucleotides of exon sequence are required in
vitro for aberrant splicing of p705 pre-mRNA substrate. This
correlates well with the minimal size of exons commonly
occurring in nature. As indicated by statistical analysis, internal
exons containing less than 50 nucleotides are rare and consti-































FIG. 7. Complete pattern of products and intermediates generated
during in vitro splicing of IVS2, p654, and p3654con pre-mRNAs. IVS2
represents the wild-type substrate, which follows a simple splicing
pathway, yielding the 400-nucleotide correct product (composed of
exons 1 and 2). The splicing of p654 thalassemic pre-mRNA results in
the generation of aberrant mRNA containing an extra 73 nucleotides
of intron sequence in addition to the correct product. The splicing
of p654con pre-mRNA, because of mutations improving the 5' splice
site at position 652, results in the generation of only the aberrant
product.
(16). The length of about 50 nucleotides was also shown to be
the lower limit for exons with weak splice sites recognizable in
model pre-mRNAs both in vivo and in vitro (9, 51). The
sequence analysis of the aberrant exon in p705 pre-mRNA did
not reveal any AG dinucleotide or more than two purines in a
row in the targeted regions (with the exception of the target for
ineffective ExU5). This indicates that the strong inhibitory
effect of 2'-O-methyl oligoribonucleotides could not be ex-
plained by the mechanism previously postulated for the splic-
ing of pre-mRNA (23, 54) or by the masking of purine-
rich sequences shown to facilitate the inclusion of exons in a
variety of pre-mRNA substrates (47, 49).
We conclude that the inhibitory effect of exon-targeted
oligonucleotides reflects the amount of space needed for
splicing factors to associate near the splice sites flanking the
internal exon. The existence of such interactions is indeed
supported by early experiments in which uncapped pre-mRNA
was used as a splicing substrate (22, 37). These experiments
showed that the region in human (-globin pre-mRNA extend-
ing approximately 20 nucleotides upstream from the exon 1 5'
splice site was protected against the activity of an endogenous
5'-to-3' exonuclease (37). The factors likely to be displaced by
the exon-targeted antisense oligonucleotides include U5 small
nuclear RNA, shown to interact with exon nucleotides adjacent
to both splice sites (33, 42, 50).
Experiments on the strength of 3' and 5' splice sites in
3654 and p654con pre-mRNAs led to the observation that the
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FIG. 8. Effects of 18-mer oligonucleotides on the splicing of pB654
(A) and p6l4con (B) pre-mRNAs. The splicing of ,B5 and ,B5c0
pre-mRNAs was carried out in the presence of increasing concentra-
tions of 18-mer oligonucleotides directed to the 3' splice site at
position 579 (lanes 2 to 4) and to the 5' splice site at position 652 (lanes
5 to 7). Lanes 1, splicing without oligonucleotide. Panel B, lane 8,
shows the splicing of pB654con pre-mRNA in the presence of noncomple-
mentary oligonucleotide (control). The concentration of oligonucleo-
tide is shown at the top of each lane. Quantitation of the results is
shown below each autoradiogram.
sequence did not significantly change its accessibility to
antisense oligonucleotides but unexpectedly resulted in the
decreased accessibility of the upstream 3' splice site. Appar-
ently, the improvement of the 5' splice site gives rise to
stronger interactions of splicing factors with the 3' splice site,
effectively displacing shorter antisense oligonucleotides tar-
geted to this site. In fact, it has been shown that U2AF65
is recruited to the 3' splice site by improved interactions of
Ul small nuclear ribonucleoproteins at the downstream 5'
splice site through a network of interactions spanning the exon
(18). Data from this work, demonstrating the existence of
functional domains within exon sequences and measurable
changes in the accessibility of flanking splice sites, provide
additional support for the exon definition model, in which
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FIG. 9. Effects of 14-mer oligonucleotides on the splicing of p654c0n (A) and 3654 (B) pre-mRNAs. (A) The splicing of 13654con pre-mRNA was
carried out in the presence of 14-mer oligonucleotides targeted to the 3' cryptic splice site (lanes 2 and 3) and the consensus 5' splice site at position
652 (lanes 4 and 5). Lane 1, splicing without oligonucleotide. (B) The splicing of p654 pre-mRNA was carried out in the presence of 14-mer
oligonucleotide targeted to the 3' cryptic splice site (lanes 2 and 3). Lane 1, splicing without oligonucleotide; lane 4, splicing with
noncomplementary oligonucleotide (control). Quantitation of the results is shown below each autoradiogram.
exons, and not introns, are the units of assembly during
spliceosome formation (36).
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